DISC-0974 Trials for Myelofibrosis and Chronic Kidney Disease Anemia

DISC-0974 Clinical Trials Targeting Myelofibrosis and Chronic Kidney Disease Anemia

Disc Medicine is conducting clinical trials for DISC-0974, an investigational agent aimed at treating anemia associated with myelofibrosis (MF) and chronic kidney disease (CKD). These trials include a Phase 1b/2a study for CKD patients not on dialysis and a separate trial for those with MF anemia. DISC-0974 is not yet approved for therapeutic use anywhere globally.

Understanding Myelofibrosis and Anemia

Myelofibrosis is a rare, chronic blood cancer affecting approximately 25,000 individuals in the United States. A major symptom of MF is severe anemia, with over 80% of patients experiencing it at diagnosis. This anemia often worsens, leading many patients to require regular red blood cell transfusions. Research indicates that hepcidin, a protein, is significantly elevated in MF patients and contributes to the severity of anemia.

About Disc Medicine

Disc Medicine is a biopharmaceutical company focused on developing treatments for serious blood disorders. Their research targets fundamental biological processes related to red blood cell biology, specifically heme biosynthesis and iron regulation.

Forward-Looking Statements

Disc Medicine has issued forward-looking statements regarding the potential outcomes of their clinical trials. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Investors are cautioned against placing undue reliance on these statements, as future events and conditions could impact the outcomes significantly.

For more information about Disc Medicine and their ongoing research, please visit their official website.